References
- 1. Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ. Overview of hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ. Haemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th ed. Philadelphia, PA: Lippincott Wiliams & Wilkins. 2006: 2-15.
- 2. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107(23 Suppl 1): 14-18.
- 3. Rosendaal FR. Venous thrombosis: Prevalence and interaction of risk factors. Haemostasis. 1999; (Suppl S1): S1-S9.
- 4. Griffin JH, Evatt B, Wideman C. Anticoagulant protein C pathway defective in majority of thrombophilia patients. Blood. 1993; 82(7): 1989-1993.
- 5. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965; 13: 516-530.
- 6. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protrombin C in congenital thrombotic disease. J Clin Invest. 1981; 68(5): 1370-1373.
- 7. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest. 1984; 74(6): 2082-2088.
- 8. Cushman M. Inherited risk factors for venous thrombosis. Hematology Am Soc Hematol Educ Program 2005: 452-457.
- 9. März W, Nauck M, Wieland H. The molecular mechanisms of inherited thrombophilia. Z Kardiol. 2000; 89(7): 575-586.
- 10. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994; 269(50): 31869-318680.
- 11. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475): 64-66.
- 12. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: Clinical implications. Semin Thromb Hemost. 1998; 24(4): 367-379.
- 13. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, et al. Increased efficiency of mRNA 3’ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001; 28(4): 389-392.
- 14. Danckwardt S, Hentze MW, Kulozik AE. 3’ End mRNA processing: Molecular mechanisms and implications for health and disease. EMBO J. 2008; 27(3): 482-498.
- 15. Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, Pforsich M, Frede U, et al. The prothrombin 3’ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood. 2004; 104(2): 428-435.
- 16. Danckwardt S, Hartmann K, Gehring NH, Hentze MW, Kulozik AE. 3’ End processing of the prothrombin mRNA in thrombophilia. Acta Haematol. 2006; 115(3-4): 192-197.
- 17. Flaujac C, Conard J, Horellou MH, Le Flem L, Samama MM. Atypical mutations of the prothrombin gene at positions 20,209 and 20,218, and a novel mutation at position 20,219. Report on 10 patients. J Thromb Haemost. 2007; 5(5): 1064-1068.
- 18. Warshawsky I, Hren C, Sercia L, Shadrach B, Deitcher SR, Newton E, et al. Detection of a novel point mutation of the prothrombin gene at position 20209. Diagn Mol Pathol. 2002; 11(3): 152-156.
- 19. Hooper C, Roberts S, Dowling N, Austin H, Lally C, Whitsett C. The prevalence of the prothrombin gene variant C20209T in African- Americans and Caucasians and lack of association with venous thromboembolism. Thromb Res. 2006; 118(6): 767-768.
- 20. Ceelie H, Bertina RM, van HylckamaVlieg A, Rosendaal FR, Vos HL. Polymorphisms in the prothrom-bin gene and their association with plasma prothrombin levels. Thromb Haemost. 2001; 85(6): 1066-1070.
- 21. Balim Z, Kosova B, Falzon K, Bezzina Wettinger S, Colak Y. Budd-Chiari syndrome in a patient heterozygous for the point mutation C20221T of the prothrombin gene. J Thromb Haemost. 2003; 1(4): 852-853.
- 22. Pérez-Ceballos E, Corral J, Alberca I, Vayá A, Llamas P, Montes R, et al. Prothrombin A19911G and G20210A polymorphisms’ role in thrombosis. J Haematol. 2002; 118(2): 610-614.
- 23. Martinelli I, Battaglioli T, Tosetto A, Legnani C, Sottile L, Ghiotto R, et al. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Tromb Haemost. 2006; 4(12): 2582-2586.
- 24. von Ahsen N, Oellerich M. The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood. 2004; 103(2): 586-593.
- 25. Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJ. The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large popula-tion-based case-control study. J Thromb Haemost. 2006; 4(12): 2587-2592.
- 26. Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic analysis of idiopathic thrombophilia. Am J Hum Genet. 2000; 67(6): 1452-1459.
- 27. Djordjevic V, Pruner I, Kovac M, Miljic P, Antonijevic N, Kojic S, et al. Three novel 3’ end pro-thrombin gene polymorphisms and their association with thrombophilia (abstract). J Thromb Haemost. 2011; 9(Suppl 2): 873S.